CD274 and bladder transitional cell carcinoma: Over the past decade, immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting programmed cell death‐1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1), have been approved for patients with advanced BLCA.